NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights

/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announces...

Related Keywords

France ,United States ,Americans ,French ,Stephen Willard ,Nasdaq ,Therapeutics Inc ,Nrx Pharmaceuticals ,Us National Institutes Of Health ,Us Patient Centered Outcomes Research Initiative ,Alvogen Inc ,Nephron Pharmaceuticals ,Lotus Pharmaceuticals Inc ,Nrxp Nrx Pharmaceuticals ,Prnewswire Nrx Pharmaceuticals Inc ,Lotus ,Specialty Pharmaceutical Company ,Company Board Of Directors ,Lotus Pharmaceuticals ,Suicidal Bipolar Depression ,Data Lock ,Investigational New Drug ,Chronic Pain ,Complicated Urinary Tract ,Centered Outcomes Research Initiative ,Electroconvulsive Therapy ,Severe Depression ,New Drug Application ,Acute Suicidality ,Complicated Urinary Tract Infection ,Qualified Infectious Disease Product ,Fast Track ,Priority Review ,Chief Executive Officer ,Urinary Tract Infection ,Monday April ,Breakthrough Therapy ,Hope Therapeutics ,Fast Track Designation ,